Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin with Radiotherapy and Temozolomide in OXPHOS+ Glioblastoma
NCT04945148Phase 2
Key facts
- Status
- Recruiting
- Start
- May 2024
- Primary completion
- May 2028
- Countries
- 2
- Sponsor
- Hôpital Foch
- Modality
- Small Molecules
- Drugs
- metformin
- Conditions
- glioblastoma (GBM)
01
Overview
Phase 2, open-label, single-arm trial of metformin in glioblastoma (GBM), sponsored by Hôpital Foch. Primary endpoint: Progression Free Survival at 24 months. Started May 2024; status: recruiting.
02
Design
1 arm- Study design
- Non-randomizedOpen-label
Metformin + RT + TMZ
Metformin combined with standard Radiotherapy and Temozolomide
03
Endpoints
Primary
Progression Free Survival
Secondary
Overall Survival
Overall Response Rate
Safety of metformin
Tolerability of metformin
Beyond the preview
Go deeper on NCT04945148.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04945148.